\ \ <u>\</u>		FATENT APPLICATION	First Inventor or Application Identifier Jacques THEZE						
			Title PEPTIDES OF IL-2 AND DERIVE ES THEREOF AND THEIR USE AS THERAPEUTIC AGENTS						
		`	Assignee Name: INSTIT	TUT PASTEUR	<u> </u>	000			
	JC685		Assignee Address: 28, 757	Rue Du Docteu 24 Paris Cedex	Ir Roux K, FRANCE	U.S. P			
	U.S. P	APPLICATION ELEMENT Sèe MPEP chapter 600 concerning utility patent a		ADDRESS TO	Assistant Commi Box Patent Appli Washington, DC	ssioner for Pagents cation 20231			
	₽ 0	Fee Transmittal Form (e.g. PTO/SB/ (Submit an original and a duplicate for fee pro	/17) rocessing)	ACC	OMPANYING APPL	ICATION PARTS			
	2.	■ Specification Total	Sheets 46	8. Applic	nment Papers (cover ation Data Sheet. S F.R. §3.73(b) Statem here is an assignee)				
	3.	■ Drawing(s) (35 U.S.C. 113) Total	Sheets 27	10. Englis	h Translation Docum	nent (if applicable) Copies of IDS			
	4.	□ Oath or Declaration Total	l Pages	States	nent (IDS)/PTO-1449 ninary Amendment	G Citations (4)			
١.		 a. □ Newly executed (original or copy) b. □ Copy from a prior application (37 C.F.R, §1.63(d)) (for continuation / divisional w/ box 17 completed) 		13. White Advance Serial No. Postcard					
F= (14. Certifi	ed Copy of Priority D gn priority is claimed)	ocument(s)			
1 197 198 1		 i. DELETION OF INVENTO Signed statement attached delet the prior application, see 37 C.F 1.33(b). 	PR(S) ting inventor(s) named in F.R. §1.63(d)(2) and	15. □ Applic See 37	ant claims small enti CFR 1.27	ty status.			
	5.	☐ CD-ROM or CD-R in duplicate, large Program (Appendix)	e table or Computer	16. ■ Othe	r: LIST OF INVEN	TOR'S NAMES AND			
(C)	6.	□ Nucleotide and/or Amino Acid Seque (if applicable, all necessary)	ence Submission		REQUEST FOR U.S.C. § 120	PRIORITY UNDER 35			
## ##		a. Computer Readable Form (CRF	·		· ·				
Ę		b. Specification or Sequence Listing or							
	i. □ CD-ROM or CD-R (2 copies); or ii. □ Paper								
r. Cj		c. Statement verifying identity of a	bove copies						
77 h	17.	. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below:							
-		☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application no.: 09/660,465							
		Prior application information: Examin	: Unit:						
Į.	or C consi wher	or CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is onsidered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon then a portion has been inadvertently omitted from the submitted application parts.							
	18.	8. Amend the specification by inserting before the first line the sentence:							
■ This application is a □ Continuation □ Division ■ Continuation-in-part (CIP) September 12, 2000, pending, which is a Continuation									
	September 12, 2000, pending, which is a Continuation of Seri of application Serial No. 09/660,465 Filed on Number 09/116,594, filed July 16, 1998, now U.S. Patent No. 6,168,785								
,		■ Which was published in English Which was not published in English							
7 P		 Which was not published in English This application claims priority of provisional application Serial 			Fi	led			
· -	19. CORRESPONDENCE ADDRESS								
1		13. CONNECT CHELICE ADDRESS							
	E								
	•	22850 (703) 413-3000 FACSIMILE: (703) 413-2220							
						04.040			
	ŀ	Name: Norman F. Oblon			Registration No.:	24,618			

Signature:

Name:

Daniel J. Rereira, Ph.D.

Date:

Registration No.:

45,518

|202930US0CIP

Attorney Docket No.

INVENTOR(S)

Jacques THEZE et al

SERIAL NO:

New Application

FILING DATE: Herewith

FOR:

PEPTIDES OF IL-2 AND DERIVATIVES THEREOF AND THEIR USE AS THERAPEUTIC AGENTS

FEE TRANSMITTAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	34 - 20 =	14	× \$18 =	\$252.00
INDEPENDENT CLAIMS	5 - 3 =	2	× \$80 =	\$160.00
■ MULTIPLE DEPENDE	\$270.00			
■ LATE FILING OF DEC	\$130.00			
	\$710.00			
	\$1,522.00			
□ REDUCTION BY 50% I	\$0.00			
FILING IN NON-ENGLISH LANGUAGE + \$130 =				\$0.00
□ RECORDATION OF AS	RECORDATION OF ASSIGNMENT + \$40 =			
			TOTAL	\$1,522.00

Please charge Deposit Account No. 15-0030 in the amount of

A duplicate copy of this sheet is enclosed.

A check in the amount of \$1,522.00

to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

ħ

02/06/01

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/00)

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,

MAJER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Daniel J. Pereira, Ph.D.

Registration No. 45,513 8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jacques THEZE et al

SERIAL NO: New U.S. Application

FILED:

Herewith

FOR:

PEPTIDES OF IL-2 AND DERIVATIVES THEREOF AND THEIR USE AS THERAPEUTIC AGENTS

REQUEST FOR PRIORITY

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

- Full benefit of the filing date of U.S. Application Serial Number 09/660,465, filed September 12, 2000, is claimed pursuant to the provisions of 35 U.S.C. §120.
- □ Full benefit of the filing date of U.S. Provisional Application Serial Number, filed, is claimed pursuant to the provisions of 35 U.S.C. §119(e).
- □ Applicants claim any right to priority from any earlier filed applications to which they may be entitled pursuant to the provisions of 35 U.S.C. §119, as noted below.

In the matter of the above-identified application for patent, notice is hereby given that the applicants claim as priority:

COUNTRY

APPLICATION NUMBER

MONTH/DAY/YEAR

Certified copies of the corresponding Convention Application(s)

- □ are submitted herewith
- will be submitted prior to payment of the Final Fee
- were filed in prior application Serial No. filed
- were submitted to the International Bureau in PCT Application Number.

 Receipt of the certified copies by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.
- ☐ (A) Application Serial No.(s) were filed in prior application Serial No. filed ; and
 - (B) Application Serial No.(s)
 - are submitted herewith
 - will be submitted prior to payment of the Final Fee

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Øblon

Registration No. 24,618

Daniel J. Pereira, Ph.D. Registration No. 45,518

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/98) Docket No.

202930US0CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jacques THEZE et al

FILING DATE: Herewith

FOR: PEPT

PEPTIDES OF IL-2 AND DERIVATIVES THEREOF AND THEIR USE AS THERAPEUTIC AGENTS

LIST OF INVENTORS' NAMES AND ADDRESSES

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Listed below are the names and addresses of the inventors for the above-identified patent application.

1) Jacques THEZE

3 rue de la Planche, 75007 Paris, FRANCE

2) Ralph ECKENBERG

27 rue A, Dumas 78100 St. Germain en Laye, FRANCE

3) Jean-Louis MOREAU

7 rue Falguiere 75015 Paris, FRANCE

4) Jean-Claude MAZIE

24, rue des Jardins 92600 Asnières-sur-Seine, FRANCE

A declaration containing all the necessary information will be submitted at a later date.

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 11/98) Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Daniel J. Pereira, Ph.D. Registration No. 45,518